[Hepatotoxicity of the tuberculostatic combination INH+RMP+EMB in relation to drug metabolism in the liver].
作者信息
Musch E, Eichelbaum M, Wang J K, von Sassen W, Ochs H R, Castro-Parra M, Dengler H J
出版信息
Med Welt. 1982 Jun 25;33(25):911-4.
PMID:7109939
Abstract
摘要
相似文献
1
[Hepatotoxicity of the tuberculostatic combination INH+RMP+EMB in relation to drug metabolism in the liver].[抗结核药物组合异烟肼+利福平+乙胺丁醇的肝毒性与肝脏药物代谢的关系]
Med Welt. 1982 Jun 25;33(25):911-4.
2
[The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
Med Welt. 1976 Feb 20;27(8):389-90.
3
4
5
The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.利福平和吡嗪酰胺对大鼠体内异烟肼药代动力学的影响。
Biopharm Drug Dispos. 2007 Nov;28(8):409-13. doi: 10.1002/bdd.570.
6
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.利福平加吡嗪酰胺与异烟肼治疗潜伏性结核感染的比较：一项荟萃分析。
Int J Tuberc Lung Dis. 2006 Oct;10(10):1080-90.
7
Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.利福平/吡嗪酰胺疗法不应用于潜伏性结核感染。
J Am Acad Dermatol. 2004 May;50(5):801; author reply 801-2. doi: 10.1016/j.jaad.2003.10.673.
8
[Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
Klin Wochenschr. 1982 May 17;60(10):513-9. doi: 10.1007/BF01756097.
9
Antituberculosis drugs and hepatotoxicity.抗结核药物与肝毒性。
Infect Genet Evol. 2004 Jun;4(2):167-70. doi: 10.1016/j.meegid.2003.01.001.
10
Acute liver failure caused by isoniazid in a child receiving carbamazepine.
Int J Tuberc Lung Dis. 1998 Jul;2(7):603-6.
Zotero 插件